QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:ACIU

AC Immune (ACIU) Stock Forecast, Price & News

$2.85
-0.05 (-1.72%)
(As of 04:31 PM ET)
Compare
Today's Range
$2.84
▼
$2.93
50-Day Range
$2.77
▼
$3.38
52-Week Range
$1.68
▼
$3.83
Volume
28,947 shs
Average Volume
413,933 shs
Market Capitalization
$238.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

AC Immune MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
461.4% Upside
$16.00 Price Target
Short Interest
Healthy
1.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of AC Immune in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to ($0.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

729th out of 972 stocks

Pharmaceutical Preparations Industry

345th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

ACIU stock logo

About AC Immune (NASDAQ:ACIU) Stock

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ACIU Price History

ACIU Stock News Headlines

September 29, 2023 | americanbankingnews.com
Head-To-Head Comparison: PyroGenesis Canada (NASDAQ:PYR) and AC Immune (NASDAQ:ACIU)
September 24, 2023 | americanbankingnews.com
AC Immune (NASDAQ:ACIU) and Trevena (NASDAQ:TRVN) Critical Analysis
September 29, 2023 | Stansberry Research (Ad)
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
September 5, 2023 | finance.yahoo.com
Are Options Traders Betting on a Big Move in AC Immune (ACIU) Stock?
September 5, 2023 | finance.yahoo.com
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
September 5, 2023 | finance.yahoo.com
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
August 7, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)
August 4, 2023 | finance.yahoo.com
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
September 29, 2023 | Altimetry (Ad)
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
August 4, 2023 | finance.yahoo.com
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
July 28, 2023 | finanznachrichten.de
AC Immune SA: AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 28, 2023 | finance.yahoo.com
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 26, 2023 | finance.yahoo.com
AC Immune SA Appoints New Chief Medical Officer
July 3, 2023 | finance.yahoo.com
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 2, 2023 | fool.com
Ac Immune (NASDAQ: ACIU)
June 30, 2023 | finance.yahoo.com
Why Shares of AC Immune Jumped This Week
June 28, 2023 | markets.businessinsider.com
AC Immune SA (ACIU) Gets a Buy from H.C. Wainwright
June 27, 2023 | msn.com
Why AC Immune Stock Skyrocketed Today
June 27, 2023 | theglobeandmail.com
Biotech Pops On FDA Fast Track Designation
June 27, 2023 | finanznachrichten.de
AC Immune SA: AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease
June 27, 2023 | msn.com
AC Immune’s stock soars 13% after FDA grants fast-track designation to Alzheimer’s treatment
June 27, 2023 | msn.com
AC Immune gains 14% on FDA fast track tag for Alzheimer’s vaccine
June 27, 2023 | finance.yahoo.com
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
June 16, 2023 | finance.yahoo.com
Private equity firms among AC Immune SA's (NASDAQ:ACIU) largest stockholders and were hit after last week's 12% price drop
June 12, 2023 | finance.yahoo.com
ACIU - AC Immune SA
May 1, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for AC Immune SA (ACIU)
April 28, 2023 | finanznachrichten.de
AC Immune SA: AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Company Calendar

Last Earnings
8/04/2023
Today
9/29/2023
Next Earnings (Estimated)
10/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACIU
CUSIP
N/A
CIK
1651625
Web
www.acimmune.com
Phone
(121) 345-9121
Fax
41-21-345-9120
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+451.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,140,000.00
Net Margins
N/A
Pretax Margin
-1,743.45%
Return on Equity
-40.98%
Return on Assets
-37.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.89
Quick Ratio
8.89

Sales & Book Value

Annual Sales
$4.12 million
Price / Sales
58.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
1.37

Miscellaneous

Outstanding Shares
83,620,000
Free Float
79,773,000
Market Cap
$242.50 million
Optionable
Not Optionable
Beta
0.67
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Andrea Pfeifer Ph.D. (Age 66)
    Co-Founder, CEO & Director
    Comp: $1.11M
  • Mr. Christopher Roberts (Age 34)
    Interim CFO & VP of Fin.
  • Mr. Piergiorgio Donati (Age 52)
    Chief Technical Operations Officer
  • Dr. Marie Kosco-Vilbois (Age 65)
    Chief Scientific Officer
  • Mr. Jean-Fabien Monin (Age 52)
    Chief Admin. Officer
  • Mr. Howard Donovan (Age 48)
    Chief HR Officer
  • Prof. Johannes Rolf Streffer M.D. (Age 54)
    Chief Medical Officer
  • Mr. Joshua Drumm Ph.D.
    Head of Investor Relations
  • Mr. Alexandre Caratsch (Age 57)
    Gen. Counsel
  • Judith Moore
    Global Head of Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ACIU Stock - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings or view top-rated stocks.

What is AC Immune's stock price forecast for 2023?

1 brokerages have issued 12 month target prices for AC Immune's shares. Their ACIU share price forecasts range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next year. This suggests a possible upside of 451.7% from the stock's current price.
View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2023?

AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 42.2% and is now trading at $2.90.
View the best growth stocks for 2023 here.

Are investors shorting AC Immune?

AC Immune saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 455,000 shares, an increase of 17.3% from the August 31st total of 388,000 shares. Based on an average trading volume of 971,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.1% of the shares of the stock are short sold.
View AC Immune's Short Interest.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ACIU earnings forecast.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) released its quarterly earnings data on Friday, August, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.22).

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV).

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $2.90.

How much money does AC Immune make?

AC Immune (NASDAQ:ACIU) has a market capitalization of $242.50 million and generates $4.12 million in revenue each year. The company earns $-74,140,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does AC Immune have?

The company employs 126 workers across the globe.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 345-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120.

This page (NASDAQ:ACIU) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -